Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (ASX:PBT) covers the month of December 2017. The document serves as a Change of Director's Interest Notice submitted to the Australian Securities Exchange (ASX) and incorporated by reference into the registrant's U.S. registration statements. The filing details a specific transaction involving Director Mr. Lawrence Gozlan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding director shareholdings and does not contain financial statements or operational metrics.
Material Changes
The primary material change disclosed is the exercise of options by Director Mr. Lawrence Gozlan on December 19, 2017.
- Transaction Type: Exercise of options under the employer share option plan.
- Securities Acquired: 1,250,000 unlisted options were acquired (converted/exercised).
- Securities Held Prior: 1,000,000 options (noted as lapsed in the prior period context).
- Securities Held After: 1,250,000 options.
- Consideration: Referenced as detailed in the Explanatory Memorandum accompanying the 2017 Notice of Annual General Meeting; specific monetary value is not stated in this text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a compliance notice regarding director interests.
Investor Verification Checklist
- Verify the specific terms and exercise price of the 1,250,000 options exercised by Mr. Gozlan by reviewing the 2017 Notice of Annual General Meeting Explanatory Memorandum.
- Confirm the current total share capital and outstanding option pool of Prana Biotechnology Limited to assess the dilution impact of this transaction.
- Review the company's most recent Form 20-F or ASX announcements for actual financial performance data, as this 6-K contains none.